An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Of an Adeno-Associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Trial Profile

An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Of an Adeno-Associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs AAV2/5 OPTIRPE65 (Primary)
  • Indications Retinal dystrophies
  • Focus Adverse reactions
  • Acronyms OPTIRPE65
  • Most Recent Events

    • 08 Feb 2017 According to a MeiraGTx media release, the company has successfully completed dosing of patients in the second cohort in its clinical trial for Leber's Congenital Amaurosis with RPE65 mutations
    • 13 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top